Galmed Prescription drugs NASDAQ: GLMD, a little-known biotech inventory, has develop into the focus as its shares have skyrocketed near 400%. By 2 pm, the inventory had traded over 80 million shares, a monumental leap from its common every day quantity of simply 75,000.

The sudden surge begs the query: What’s driving this small-cap biotech to such heights, and will traders contemplate leaping in?

First, What Is Galmed Prescription drugs?

Galmed Prescription drugs is a small-cap biopharmaceutical firm headquartered in Tel Aviv, Israel. Its major focus is creating therapeutics for liver ailments, primarily concentrating on non-alcoholic steatohepatitis (NASH). The corporate’s main product, Aramchol, is an oral remedy at the moment in Part III trials for treating NASH in sufferers with weight problems and sort II diabetes.

Galmed can also be investigating Aramchol for different circumstances, together with liver illness associated to HIV, by way of the ARRIVE examine. Moreover, the corporate is creating a 5-amino-acid artificial peptide, Amilo-5MER, and has partnerships with Samil Pharma and OnKai.

Why Did Galmed Surge Right this moment?

Two key causes are behind at this time’s dramatic surge in Galmed’s inventory value, one in all which is way extra important than the opposite.

1) Regaining Nasdaq Compliance (Minor Catalyst) 

Galmed’s 6k SEC filing on September 16, 2024, revealed that the corporate had regained compliance with Nasdaq’s minimal bid value requirement. Beforehand, the inventory had fallen beneath the $1.00 threshold for 30 consecutive days, placing it in peril of delisting. Whereas this information attracted consideration, it’s inadequate to elucidate the explosive 400% rise. As an alternative, this announcement acted as a spark, bringing extra eyes to the inventory.

2) Brief Squeeze Pushed by Technical Components (Main Catalyst)

The actual driver behind the surge lies in Galmed’s distinctive inventory construction and buying and selling dynamics. The inventory is prone to supply-demand imbalances, with a tiny float of solely round 600,000 shares. Right this moment’s buying and selling quantity noticed an RVOL at 2 pm (Relative Quantity) of over 600, that means the inventory was buying and selling 600 occasions greater than its common every day quantity. When provide is that this restricted and demand spikes, because it did at this time, shares can expertise epic quick squeezes, pushing costs greater in a brief interval.

The provision of inventory locates (shares obtainable for brief promoting) throughout varied buying and selling platforms additional fueled the surge. Brief sellers, betting on the inventory’s decline, have persistently been pressured to purchase again shares at ever-increasing costs as demand vastly outweighs provide within the quick time period, making a textbook quick squeeze of large proportions.

Is Galmed a Good Play for Lively Traders Searching for Excessive Returns?

Whereas Galmed’s surge has captured consideration, the reply as to whether you must make investments largely is determined by your threat tolerance. For long-term traders, the reply is probably going no. The inventory’s volatility, low liquidity, and susceptibility to dramatic value swings make it higher suited to short-term merchants who can capitalize on intraday strikes.

This inventory’s monumental potential for each beneficial properties and losses makes it interesting for day merchants however harmful for these in search of a steady, long-term funding. The mixture of a tiny float, buying and selling inefficiencies, and supply-demand imbalances signifies that whereas the inventory may rise one other 200%, it may simply as shortly retrace most of its intraday transfer.

Earlier than you contemplate Galmed Prescription drugs, you will need to hear this.

MarketBeat retains observe of Wall Avenue’s top-rated and finest performing analysis analysts and the shares they advocate to their shoppers each day. MarketBeat has recognized the 5 shares that high analysts are quietly whispering to their shoppers to purchase now earlier than the broader market catches on… and Galmed Prescription drugs wasn’t on the listing.

Like this text? Share it with a colleague.

Hyperlink copied to clipboard.